Cartesian Therapeutics (RNAC) Equity Average (2016 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Equity Average data on file, last reported at -$137.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at -$137.2 million, down 859.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$137.2 million (down 859.6% YoY), and the FY2025 annual result was -$66.5 million, up 70.24% from the prior year.
• Equity Average retreated to -$137.2 million in Q1 2026 per RNAC's latest filing, from -$81.0 million in the prior quarter.
• Over five years, Equity Average peaked at $89.4 million in Q4 2022 and troughed at -$278.5 million in Q1 2024.
• A 5-year average of -$22.9 million and a median of -$12.2 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average surged 4615.96% in 2022, then plunged 2579.07% in 2025.
• A 5-year view of Equity Average shows it stood at $89.4 million in 2022, then sank by 312.52% to -$189.9 million in 2023, then soared by 98.41% to -$3.0 million in 2024, then sank by 2579.07% to -$81.0 million in 2025, then sank by 69.27% to -$137.2 million in 2026.
• Business Quant data shows RNAC's Equity Average at -$137.2 million in Q1 2026, -$81.0 million in Q4 2025, and -$19.2 million in Q3 2025.